Stephan Herrera

Stephan Herrera –


Stephan Herrera is VP, Strategy & Public Affairs at Basel, Switzerland-based Evolva , which is developing health, wellness, and nutritional ingredients through next-generation yeast-based fermentation. The Company has additional operations in Denmark, India, and the US. Herrera is based in California in the Bay Area.

Prior to Evolva, Herrera was Sr Director of Investor Relations and Corporate Affairs at Nektar Therapeutics. Before that, he held the same position at Sirna Therapeutics, the RNAi-focused biotech acquired by Merck for $1.2B.

Prior to his operational roles in biotech, Herrera was a reporter and editor who specialized in the global business, science and politics of biotechnology, industrial biotech, and nanotechnology. His 18 years in the field included staff reporting/editing positions at leading magazines such as Forbes, Red Herring, Nature Biotechnology and the Acumen Journal of Life Sciences. He was also a longtime contributor to the Economist and a contributing editor at MIT Technology Review.